DOI : 10.1055/s-00000059

Pneumologie

Ausgabe S 01 · Volume 71 · März 2017 DOI: 10.1055/s-007-33496

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
58. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
IC Stuttgart, 22.–25.03.2017

Kongresspräsidenten: Prof. Dr. med. Martin Hetzel, Stuttgart, Prof. Dr. med. Martin Kohlhäufl, Gerlingen; Kongresssekretär: Dr. med. Markus Zenner, Stuttgart
Abstracts (HTML) Autorenliste
P112
Albers, FC; Price, RG; Yancey, SW; Bradford, E: ENCORE: Effect of Mepolizumab in Severe Eosinophilic Asthma Patients Eligible for Omalizumab Treatment
P114
Albers, FC; Cockle, S; Gunsoy, N; Shin, JY; Nelsen, LM; Müllerová, H: Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL Study
P116
Pouliquen, I; Austin, D; Gunsoy, N; Yancey, SW: ENCORE: A weight-based exacerbation dose response analysis of mepolizumab in severe asthma with eosinophilic phenotype
P226
Hinds, D; Chapman, KR; Piazza, P; Gibbs, M; Raherison, C; Gaalswyk, K; Greulich, T; Lin, J; Adachi, M; Davis, K: Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)
P253
Gruffydd-Jones, K; Thomas, M; Rodriguez, MR; Infantino, A; Opitz, K; Hargreaves, V: Asthma impacts on work productivity and daily activities in employed patients who are symptomatic despite background therapy: a multi-national survey
P481
Ulrich-Merzenich, G; Juergens, LJ; Shcherbakova, A; Tüschen, A; Tuleta, I; Juergens, U: Kontrolle der erhöhten ex vivo Th1/Th2-Aktivität bei Asthma durch Omalizumab in vitro
P431
Hamelmann, E; Szefler, SJ; Bernstein, JA; Murphy, K; El Azzi, G; Engel, M; Moroni-Zentgraf, P; Sigmund, R: Efficacy of tiotropium in patients aged 6 – 17 years with severe symptomatic asthma
P432
Vogelberg, C; Szefler, SJ; Hamelmann, E; Boner, A; Moroni-Zentgraf, P; Engel, M; El Azzi, G; Finnigan, H; Vandewalker, M: Safety of tiotropium Respimat add-on therapy in patients aged 6 – 17 years with symptomatic asthma